This patent portfolio comprises two complementary vascular therapy technologies focused on blood flow modulation and compression-based treatment systems for human and veterinary applications. Developed at the intersection of pharmacology and biomedical engineering, the portfolio addresses unmet needs in chronic wound care and circulatory dysfunction. These non-invasive solutions are designed to improve tissue perfusion, enhance healing outcomes, and reduce overall treatment burden across high-cost clinical and veterinary settings.

The first technology, Procardia and the Five Calcium Channel Blockers, is a proprietary transdermal vasodilatory formulation designed to enhance peripheral circulation and accelerate healing in complex wound environments, including diabetic and ischemic ulcers. By leveraging targeted calcium channel modulation and vasodilatory mechanisms, it improves localized microvascular blood flow to support tissue regeneration and reduce healing time in patients with severe comorbidities.

The second technology, the Reverse Peristolic Pneumatic Compression and Vascular Rehabilitation Device,, is a patented sequential compression and rehabilitation system engineered for equine applications to improve distal limb circulation and address vascular dysfunction associated with laminitis and other lower-leg conditions in horses. Using controlled inflatable chamber dynamics within a specialized boot, the system provides a non-invasive therapeutic and recuperative solution for a broad range of vascular leg injuries, while also supporting recovery and performance maintenance in high-value equine athletes involved in racing, jumping, hunting, and other sporting activities. Designed to enhance circulation, reduce recovery time, and promote long-term mobility, the technology offers improved clinical and functional outcomes across both treatment and rehabilitation settings.